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Abstract
Timing for the evaluation and listing of patients with cystic fibrosis who are candidates for lung transplantation is still uncertain.
Our study goal was to determine the value of the 12-min walk test as a simple and easy-to-use adjunctive assessment tool for
pre-transplant evaluation. A total of 34 cystic fibrosis patients (17 male, mean age 22 years) with end-stage lung disease were
evaluated in this retrospective analysis. The 12-min walk test was carried out according to an established protocol. Before walking,
body plethysmography was performed and a capillary sample was taken for blood gas analysis. Walking distance and SaO via2
continuous pulse oximetry were recorded online. There was a strong correlation between survival time and walking distance (rs
0.7, Ps0.003). No other single parameter, such as FEV , SaO pCO or BMI, showed a statistically significant correlation with1 2, 2
survival time. Subjects who walked F700 m had a lower cumulative survival (Ps0.02). There was a statistically significant
positive correlation between walking distance and SaO at rest and after 12 min of walking (rs0.5, Ps0.001; and rs0.5, Ps2
0.04, respectively). There was no correlation between walking distance and pCO at rest, BMI, FEV , or degree of change in2 1
SaO during the walk test. This study demonstrates that in CF patients with end-stage lung disease, walking distance during a2
12-min walk test is more informative with respect to survival than single parameters such as SaO pCO , FEV or BMI.2, 2 1
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Currently, lung transplantation (LTX) provides the
only opportunity to prolong survival for cystic fibrosis
(CF) patients with end-stage lung disease w1x. This
procedure often leads to an improved quality of life, but
also carries a primary risk of acute lung failure, hem-
orrhage, rejection or infection w2x.
Due to the limited supply of donor organs, the annual
number of transplantations has leveled off and waiting
times for adults have increased w3,4x. Consequently, it
is important to be placed on the waiting list at an
appropriate time. There are guidelines for the selection
of LTX candidates w5,6x, but the clinical course of the
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patients is extremely variable and the decision has to be
individualized. Furthermore, there is a need to regularly
re-evaluate the criteria.
In 1976, McGavin et al. introduced the 12-min walk-
ing test as a measure of exercise capacity for subjects
with chronic lung disease w7x. The majority of subse-
quent publications have analyzed walk tests in subjects
with chronic obstructive pulmonary disease (COPD)
w8–10x. As little information is available on the predic-
tive value of walk tests in subjects with end-stage cystic
fibrosis w11x, we studied performance in a standardized
12-min walk test as a parameter for evaluating CF
patients for LTX by addressing the following questions:
1. Is there a correlation between survival time and
walking distance, pCO , oxyhemoglobin saturation2
(SaO ) at rest or after 12 min of walking, decrease2
in SaO , forced expiratory volume in 1 s (FEV ), or2 1
body mass index (BMI)?
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Table 1
Characteristics of CF patients assessed for LTX
Mean Median S.D. Range
SaO at rest (%) (ns33)2 89 89 4.6 81–97
SaO at 6 min (%) (ns25)2 81 78 7.7 68–94
SaO at 12 min (%) (ns30)2 79 78 8.5 63–95
Walking distance (m) (ns34) 779 750 257 120–1300
FEV predicted (%) (ns34)1 26 24 9.4 14–52
VC predicted (%) (ns33) 40 39 10.9 24–69
pCO (mmHg) (ns32)2 47 44 9.3 32–71
pO (mmHg) (ns32)2 59 57 10.3 41–89
BMI (ns33) 16.6 16.9 2.1 13–21
Results of the 12-min walk test, blood gas analyses, spirometric
data and BMI of CF patients assessed for LTX (ns34; 17 m, 17 f).
1 mmHg(0.133 kPa.
2. Is the walking distance predictive with respect to
probability of survival?
3. Is there a correlation between walking distance and
SaO at rest, SaO after exercise, the decrease in2 2
SaO during the 12-min walk, pCO , FEV or BMI?2 2 1
2. Materials and methods
2.1. Subjects
Between January 1995 and December 1999, the 12-
min walk test was performed in 34 cystic fibrosis
patients (17 male, 17 female) at the time of assessment
for lung transplantation. Subjects with an acute pulmo-
nary exacerbation were excluded. Ages ranged from 12
to 40 years (mean 22). A total of 15 subjects (8 male,
7 female) died during the following months or years
prior to transplantation. Ages ranged from 17 to 40
years (mean 24). We analyzed results obtained for all
subjects (total group) and for subjects who died (sub-
group), as well as according to gender.
2.2. Functional data
All spirometric data (body plethysmograph, Jager,¨
Wurzburg, Germany) were expressed as percentage¨
predicted. Subjects were breathing ambient air. An
arterialized blood sample was taken from a hyperemic
(by topical Nonivamid and Nicoboxil, Boehringer, Ingel-
heim) lobe of the ear and analyzed using a blood gas
analyzer (AVL 990, Medizintechnik GmbH, Germany).
The walk test was carried out along a level, enclosed
hospital corridor according to the method described by
McGavin et al. w7x. Two tests were performed whenever
possible on two consecutive days at approximately the
same time of day. The test with the greater distance was
used for analysis. The performance of more tests was
difficult because of time constraints and the clinical
condition of our patients w12,13x. Each subject was
instructed to walk as far as possible in 12 min, resting
only when necessary. All tests were supervised by the
same investigator, who accompanied each subject, acting
as a timekeeper and giving encouragement w14x. As is
common practice in exercise testing, pulse oximetry was
used to measure SaO during the walk, because it is2
simple and non-invasive. SaO measurements were2
recorded at 60-s intervals with a hand-held oximeter
(Nellcor, NPB-40, Idstein, Germany). The oximeter was
held by the investigator at a comfortable distance from
the patient throughout the test. The subject’s arm was
placed in a sling to hold the hand and finger probe in a
horizontal position and to provide stable measurements.
The distance covered in 12 min was recorded.
2.3. Statistical analyses
For statistical analysis, we used SPSS for Windows
version 8.0 (SPSS Inc, Chicago, IL, USA). Spearman’s
non-parametric correlation was used to examine corre-
lations between the walking distance in a walk test and
FEV , BMI, pCO or pO at rest, SaO at rest, after 61 2 2 2
and after 12 min of walking, or drop in SaO . The same2
test was used to check whether there was an association
between survival time and the above-mentioned
parameters.
Kaplan–Meier survival analysis was used for the
probability of survival.
P-0.05 was taken as the critical significance level.
For technical reasons, complete sets of data were not
available for every patient. The number of subjects
included in the calculations is indicated in Section 3
and in the tables and figures.
3. Results
Characteristics of all subjects assessed (ns34) are
indicated in Table 1. At rest all subjects were hypoxic
and 40% were hypercapnic. The mean walking distance
was below 800 m. During the 12-min walk, SaO2
decreased by a mean of 10%.
During the following months or years, 15 patients
died prior to transplantation with a median time to death
of 11 (3–28) months. Seven patients were transplanted
and 12 were still on the waiting list when analysis was
performed.
3.1. Correlation between survival time and different
parameters
In the subgroup of subjects who died over the follow-
ing months or years (ns15), we studied whether there
was a correlation between survival time and FEV , BMI,1
pCO at rest, SaO before or after 12 min of walking,2 2
decrease in SaO or the walking distance. Survival time2
was defined as the time interval from performance of
the walk test until death in months.
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Fig. 1. Walking distance after 12 min plotted against survival time (rs0.69, Ps0.02) in a subgroup of CF patients who died while on the waiting
list (ns15). No subject who walked F650 m survived for more than 10 months.
There was good correlation between survival time
and walking distance (rs0.7, Ps0.003) (Fig. 1), but
there was no correlation between survival time and
SaO at rest (rs0.3, Ps0.2), SaO after 12 min of2 2
walking (rsy0.1, Ps0.7), decrease in SaO (rs0.2,2
Ps0.6), pCO (rsy0.5, Ps0.07), FEV (rs0.2, Ps2 1
0.5) or BMI (rs0.02, Ps0.9).
No subject who walked less than 650 m survived
more than 10 months.
3.2. Walking distance and probability of survival
We examined if subjects who walked F700 m had a
lower cumulative probability of survival than subjects
who walked )700 m if they were not transplanted (ns
27). Within the patients that died on the list (ns15; 7
m, 8 f) females were slightly more frequent in the group
that walked F700 m (ns8; 3 m, 5 f) compared to the
group that walked )700 m (ns7; 4 m, 3 f). The
Kaplan–Meier survival curve indicates a significantly
lower survival time in subjects who walked F700 m
than in subjects who walked )700 m (Ps0.02; Fig.
2). Results were similar when transplanted patients were
included (ns34, Ps0.01).
3.3. Correlation between walking distance and different
parameters
SaO at rest (rs0.5, Ps0.001) and after 12 min of2
walking (rs0.5, Ps0.004) were positively correlated
with the walking distance. There was no correlation
between the walking distance after 12 min and BMI
(rs0.08, Ps0.7), pCO at rest (rsy0.01, Ps0.9),2
FEV (rs0.3, Ps0.08), SaO after 6 min of walking1 2
(rs0.4, Ps0.07) or fall in SaO during the walk test2
(rsy0.3, Ps0.1).
4. Discussion
This retrospective analysis evaluates the utility of the
12-min walk test as a simple and easy-to-use assessment
tool for LTX in CF patients. We determined the exercise
tolerance of CF subjects with advanced disease in
relation to their subsequent survival. Many of our
patients were referred for LTX assessment in the end
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Fig. 2. Kaplan–Meier survival curve for all CF patients who were assessed for LTX but not transplanted (ns27): 50% of subjects who walked
F700 m (ns11) died during the first 8 months; 50% of subjects who walked )700 m (ns16) survived more than 20 months.
stage of their disease (Table 1). This is, however, the
group which profits most from LTX w15x.
The first question addressed is whether there is a
correlation between survival time and walking distance,
pCO , pO , SaO at rest or after 12 min of walking,2 2 2
decrease in SaO , FEV or BMI. Our results indicate a2 1
significant correlation between walking distance and
survival time in the subgroup of subjects who died. A
walking distance of -650 m appears to be a marker
that the subject is at high risk. No other single parameter,
such as BMI, FEV , pO and pCO at rest, SaO at rest,1 2 2 2
SaO after 12 min of walking or decrease in SaO was2 2
significantly correlated with survival time.
In addition, Kaplan–Meier survival analyses indicated
a significantly lower time of survival in subjects who
walkedF700 m than in subjects with a walking distance
)700 m. The fact that females were more frequent in
the group who walked -700 m suggests that they were
referred late due to a rapid decline in their overall
condition. The correlation between walking distance and
survival time was confirmed by results from transplanted
patients who were analyzed separately because of a
potential bias generated by supposedly greater physical
fitness enabling them to survive until their
transplantation.
Few results from walk tests have been related to
survival of different patient groups with pulmonary
diseases in the literature. Kadikar et al. w11x demonstrat-
ed that walking distances differed significantly between
CF recipients who died and those who did not die while
on the waiting list (mean 367"112 vs. 505"94 m in a
6-min walk test). Their results cannot be directly com-
pared to ours, however, as they included subjects with
oxygen supplementation while walking.
FEV has been described as the gold standard for1
predicting survival in CF patients. In 1992, Kerem et al.
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reported that the best predictor of 2-year mortality in
the Toronto CF patient population was FEV -30% of1
the predicted value for height and sex in children and
adolescents of both genders, as well as adult women.
Subjects with FEV -30% of predicted had a 2-year1
mortality of more than 50% w16x. For men, the threshold
was a FEV -20% predicted. However, assessment1
criteria are becoming more individualized w15x. Recent
studies have demonstrated that FEV -30% may no1
longer be considered as an accurate predictor of 50%
mortality after 2 years in cystic fibrosis lung transplant
candidates w17x. Milla et al. showed that with FEV -1
30% predicted the median survival (50%) is 3.9 years.
In addition, they demonstrated that the individual annual
rate of decline of FEV was a more useful parameter to1
predict the risk of death w17x.
Other authors have described a significant correlation
between FEV and walking distance in subjects with1
obstructive airway disease w12,18x. In our patient group
there was a lack of correlation between FEV and1
walking distance. Walking distance is probably influ-
enced by a combination of factors, including cardiores-
piratory adaptation, pulmonary hypertension, hypoxemia
and muscular fitness, the functional status of the respi-
ratory and cardiovascular systems, and neuromuscular
function, as well as motivation and endurance w11,14x.
One could speculate that airway obstruction affects
exercise tolerance in the earlier stages of the disease,
whereas in our patient group, where FEV was approx-1
imately predicted as 25%, walking capacity is influenced
to a greater degree by reduced diffusion and increased
oxygen consumption, as well as physical conditioning.
It may also be reasonable to assume that exercise is
associated with worsening in VyQ mismatching due to
increased perfusion to poorly ventilated areas as cardiac
output increases with exercise.
An important question is whether the test provides
information that could not be obtained by procedures
performed at rest. Our study demonstrates that SaO2
before as well as after 12 min of walking was positively
correlated with walking distance, whereas pCO was2
not. One possible explanation might be that diffusion
capacity and oxygen consumption w11x play an important
role. As long as there is no critical obstruction and
hyperinflation, pCO , which is a marker of hypoventi-2
lation, does not seem to be critical for the exercise
limitation.
For the individual patient, a follow-up of the perform-
ance in exercise tests may be critical. Intraindividual
changes or trends of exercise tolerance over months or
years might be especially informative and will hopefully
be addressed in future studies.
5. Conclusion
Our results indicate that walking distance during a
12-min walk test is more informative with respect to
survival than single parameters such as SaO pCO ,2, 2
pO FEV or BMI. We conclude that walk tests are2, 1
simple investigations and suitable assessment criteria for
LTX in CF patients, which should be investigated in
comparison to new screening systems. w15x
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